Active Pharmaceutical Ingredient (API) Market in US 2024-2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	147 Pages	TechNavio	February, 2024	INF18578078

Best Price Guarantee
Price	from $2,500
Length	147 Pages
Publisher	TechNavio
Published Date	February, 2024
SKU	INF18578078

Active Pharmaceutical Ingredient (API) Market In US 2024-2028

The active pharmaceutical ingredient (API) market in US is forecasted to grow by USD 16.51 bn during 2023-2028, accelerating at a CAGR of 7.87% during the forecast period. The report on the active pharmaceutical ingredient (API) market in US provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by an increasing number of type II drug master files (DMF), the growing prevalence of chronic conditions, and increasing demand for biopharmaceuticals and biosimilars.

Technavio's active pharmaceutical ingredient (API) market in US is segmented as below:

By Type

Captive API
Contract API

By Product

Generic
Innovative

By Application

Oncology
Cardiovascular diseases
Diabetes
Communicable diseases
Orthopedic and others

This study identifies the paradigm shift in API manufacturing as one of the prime reasons driving the active pharmaceutical ingredient (API) market in US growth during the next few years. Also, increasing patent exercises and a growing focus on the production of high-value APIs will lead to sizable demand in the market.

The report on the active pharmaceutical ingredient (API) market in US covers the following areas:

Active pharmaceutical ingredient (API) market in US sizing
Active pharmaceutical ingredient (API) market in US forecast
Active pharmaceutical ingredient (API) market in US industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading active pharmaceutical ingredient (API) market in US vendors that include AbbVie Inc., Amneal Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd., Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., Cambrex Corp., Cipla Ltd., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Koninklijke DSM NV, Lupin Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc.. Also, the active pharmaceutical ingredient (API) market in US analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

1 Executive Summary: 1.1 Market overview; Exhibit 01: Executive Summary - Chart on Market Overview; Exhibit 02: Executive Summary - Data Table on Market Overview; Exhibit 03: Executive Summary - Chart on Country Market Characteristics; Exhibit 04: Executive Summary - Chart on Market Segmentation by Type; Exhibit 05: Executive Summary - Chart on Market Segmentation by Product; Exhibit 06: Executive Summary - Chart on Market Segmentation by Application; Exhibit 07: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Exhibit 08: Parent market; Exhibit 09: Market Characteristics
3 Market Sizing: 3.1 Market definition; Exhibit 10: Offerings of vendors included in the market definition; 3.2 Market segment analysis; Exhibit 11: Market segments; 3.3 Market size 2023; 3.4 Market outlook: Forecast for 2023-2028; Exhibit 12: Chart on US - Market size and forecast 2023-2028 ($ billion); Exhibit 13: Data Table on US - Market size and forecast 2023-2028 ($ billion); Exhibit 14: Chart on US: Year-over-year growth 2023-2028 (%); Exhibit 15: Data Table on US: Year-over-year growth 2023-2028 (%)
4 Historic Market Size: 4.1 Active pharmaceutical ingredient (API) market in US 2018 - 2022; Exhibit 16: Historic Market Size - Data Table on active pharmaceutical ingredient (api) market in US 2018 - 2022 ($ billion); 4.2 Type Segment Analysis 2018 - 2022; Exhibit 17: Historic Market Size - Type Segment 2018 - 2022 ($ billion); 4.3 Product Segment Analysis 2018 - 2022; Exhibit 18: Historic Market Size - Product Segment 2018 - 2022 ($ billion); 4.4 Application Segment Analysis 2018 - 2022; Exhibit 19: Historic Market Size - Application Segment 2018 - 2022 ($ billion)
5 Five Forces Analysis: 5.1 Five forces summary; Exhibit 20: Five forces analysis - Comparison between 2023 and 2028; 5.2 Bargaining power of buyers; Exhibit 21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; 5.3 Bargaining power of suppliers; Exhibit 22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; 5.4 Threat of new entrants; Exhibit 23: Threat of new entrants - Impact of key factors in 2023 and 2028; 5.5 Threat of substitutes; Exhibit 24: Threat of substitutes - Impact of key factors in 2023 and 2028; 5.6 Threat of rivalry; Exhibit 25: Threat of rivalry - Impact of key factors in 2023 and 2028; 5.7 Market condition; Exhibit 26: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Type: 6.1 Market segments; Exhibit 27: Chart on Type - Market share 2023-2028 (%); Exhibit 28: Data Table on Type - Market share 2023-2028 (%); 6.2 Comparison by Type; Exhibit 29: Chart on Comparison by Type; Exhibit 30: Data Table on Comparison by Type; 6.3 Captive API - Market size and forecast 2023-2028; Exhibit 31: Chart on Captive API - Market size and forecast 2023-2028 ($ billion); Exhibit 32: Data Table on Captive API - Market size and forecast 2023-2028 ($ billion); Exhibit 33: Chart on Captive API - Year-over-year growth 2023-2028 (%); Exhibit 34: Data Table on Captive API - Year-over-year growth 2023-2028 (%); 6.4 Contract API - Market size and forecast 2023-2028; Exhibit 35: Chart on Contract API - Market size and forecast 2023-2028 ($ billion); Exhibit 36: Data Table on Contract API - Market size and forecast 2023-2028 ($ billion); Exhibit 37: Chart on Contract API - Year-over-year growth 2023-2028 (%); Exhibit 38: Data Table on Contract API - Year-over-year growth 2023-2028 (%); 6.5 Market opportunity by Type; Exhibit 39: Market opportunity by Type ($ billion); Exhibit 40: Data Table on Market opportunity by Type ($ billion)
7 Market Segmentation by Product: 7.1 Market segments; Exhibit 41: Chart on Product - Market share 2023-2028 (%); Exhibit 42: Data Table on Product - Market share 2023-2028 (%); 7.2 Comparison by Product; Exhibit 43: Chart on Comparison by Product; Exhibit 44: Data Table on Comparison by Product; 7.3 Generic - Market size and forecast 2023-2028; Exhibit 45: Chart on Generic - Market size and forecast 2023-2028 ($ billion); Exhibit 46: Data Table on Generic - Market size and forecast 2023-2028 ($ billion); Exhibit 47: Chart on Generic - Year-over-year growth 2023-2028 (%); Exhibit 48: Data Table on Generic - Year-over-year growth 2023-2028 (%); 7.4 Innovative - Market size and forecast 2023-2028; Exhibit 49: Chart on Innovative - Market size and forecast 2023-2028 ($ billion); Exhibit 50: Data Table on Innovative - Market size and forecast 2023-2028 ($ billion); Exhibit 51: Chart on Innovative - Year-over-year growth 2023-2028 (%); Exhibit 52: Data Table on Innovative - Year-over-year growth 2023-2028 (%); 7.5 Market opportunity by Product; Exhibit 53: Market opportunity by Product ($ billion); Exhibit 54: Data Table on Market opportunity by Product ($ billion)
8 Market Segmentation by Application: 8.1 Market segments; Exhibit 55: Chart on Application - Market share 2023-2028 (%); Exhibit 56: Data Table on Application - Market share 2023-2028 (%); 8.2 Comparison by Application; Exhibit 57: Chart on Comparison by Application; Exhibit 58: Data Table on Comparison by Application; 8.3 Oncology - Market size and forecast 2023-2028; Exhibit 59: Chart on Oncology - Market size and forecast 2023-2028 ($ billion); Exhibit 60: Data Table on Oncology - Market size and forecast 2023-2028 ($ billion); Exhibit 61: Chart on Oncology - Year-over-year growth 2023-2028 (%); Exhibit 62: Data Table on Oncology - Year-over-year growth 2023-2028 (%); 8.4 Cardiovascular diseases - Market size and forecast 2023-2028; Exhibit 63: Chart on Cardiovascular diseases - Market size and forecast 2023-2028 ($ billion); Exhibit 64: Data Table on Cardiovascular diseases - Market size and forecast 2023-2028 ($ billion); Exhibit 65: Chart on Cardiovascular diseases - Year-over-year growth 2023-2028 (%); Exhibit 66: Data Table on Cardiovascular diseases - Year-over-year growth 2023-2028 (%); 8.5 Diabetes - Market size and forecast 2023-2028; Exhibit 67: Chart on Diabetes - Market size and forecast 2023-2028 ($ billion); Exhibit 68: Data Table on Diabetes - Market size and forecast 2023-2028 ($ billion); Exhibit 69: Chart on Diabetes - Year-over-year growth 2023-2028 (%); Exhibit 70: Data Table on Diabetes - Year-over-year growth 2023-2028 (%); 8.6 Communicable diseases - Market size and forecast 2023-2028; Exhibit 71: Chart on Communicable diseases - Market size and forecast 2023-2028 ($ billion); Exhibit 72: Data Table on Communicable diseases - Market size and forecast 2023-2028 ($ billion); Exhibit 73: Chart on Communicable diseases - Year-over-year growth 2023-2028 (%); Exhibit 74: Data Table on Communicable diseases - Year-over-year growth 2023-2028 (%); 8.7 Orthopedic and others - Market size and forecast 2023-2028; Exhibit 75: Chart on Orthopedic and others - Market size and forecast 2023-2028 ($ billion); Exhibit 76: Data Table on Orthopedic and others - Market size and forecast 2023-2028 ($ billion); Exhibit 77: Chart on Orthopedic and others - Year-over-year growth 2023-2028 (%); Exhibit 78: Data Table on Orthopedic and others - Year-over-year growth 2023-2028 (%); 8.8 Market opportunity by Application; Exhibit 79: Market opportunity by Application ($ billion); Exhibit 80: Data Table on Market opportunity by Application ($ billion)
9 Customer Landscape: 9.1 Customer landscape overview; Exhibit 81: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
10 Drivers, Challenges, and Trends: 10.1 Market drivers; 10.2 Market challenges; 10.3 Impact of drivers and challenges; Exhibit 82: Impact of drivers and challenges in 2023 and 2028; 10.4 Market trends
11 Vendor Landscape: 11.1 Overview; 11.2 Vendor landscape; Exhibit 83: Overview on Criticality of inputs and Factors of differentiation; 11.3 Landscape disruption; Exhibit 84: Overview on factors of disruption; 11.4 Industry risks; Exhibit 85: Impact of key risks on business
12 Vendor Analysis: 12.1 Vendors covered; Exhibit 86: Vendors covered; 12.2 Market positioning of vendors; Exhibit 87: Matrix on vendor position and classification; 12.3 AbbVie Inc.; Exhibit 88: AbbVie Inc. - Overview; Exhibit 89: AbbVie Inc. - Product / Service; Exhibit 90: AbbVie Inc. - Key news; Exhibit 91: AbbVie Inc. - Key offerings; 12.4 Amneal Pharmaceuticals Inc.; Exhibit 92: Amneal Pharmaceuticals Inc. - Overview; Exhibit 93: Amneal Pharmaceuticals Inc. - Business segments; Exhibit 94: Amneal Pharmaceuticals Inc. - Key news; Exhibit 95: Amneal Pharmaceuticals Inc. - Key offerings; Exhibit 96: Amneal Pharmaceuticals Inc. - Segment focus; 12.5 Aurobindo Pharma Ltd.; Exhibit 97: Aurobindo Pharma Ltd. - Overview; Exhibit 98: Aurobindo Pharma Ltd. - Product / Service; Exhibit 99: Aurobindo Pharma Ltd. - Key offerings; 12.6 Cadila Pharmaceuticals Ltd.; Exhibit 100: Cadila Pharmaceuticals Ltd. - Overview; Exhibit 101: Cadila Pharmaceuticals Ltd. - Product / Service; Exhibit 102: Cadila Pharmaceuticals Ltd. - Key offerings; 12.7 Cipla Ltd.; Exhibit 103: Cipla Ltd. - Overview; Exhibit 104: Cipla Ltd. - Business segments; Exhibit 105: Cipla Ltd. - Key news; Exhibit 106: Cipla Ltd. - Key offerings; Exhibit 107: Cipla Ltd. - Segment focus; 12.8 Dr Reddys Laboratories Ltd.; Exhibit 108: Dr Reddys Laboratories Ltd. - Overview; Exhibit 109: Dr Reddys Laboratories Ltd. - Business segments; Exhibit 110: Dr Reddys Laboratories Ltd. - Key offerings; Exhibit 111: Dr Reddys Laboratories Ltd. - Segment focus; 12.9 GlaxoSmithKline Plc; Exhibit 112: GlaxoSmithKline Plc - Overview; Exhibit 113: GlaxoSmithKline Plc - Business segments; Exhibit 114: GlaxoSmithKline Plc - Key news; Exhibit 115: GlaxoSmithKline Plc - Key offerings; Exhibit 116: GlaxoSmithKline Plc - Segment focus; 12.10 Koninklijke DSM NV; Exhibit 117: Koninklijke DSM NV - Overview; Exhibit 118: Koninklijke DSM NV - Business segments; Exhibit 119: Koninklijke DSM NV - Key news; Exhibit 120: Koninklijke DSM NV - Key offerings; Exhibit 121: Koninklijke DSM NV - Segment focus; 12.11 Lupin Ltd.; Exhibit 122: Lupin Ltd. - Overview; Exhibit 123: Lupin Ltd. - Product / Service; Exhibit 124: Lupin Ltd. - Key news; Exhibit 125: Lupin Ltd. - Key offerings; 12.12 Novartis AG; Exhibit 126: Novartis AG - Overview; Exhibit 127: Novartis AG - Business segments; Exhibit 128: Novartis AG - Key offerings; Exhibit 129: Novartis AG - Segment focus; 12.13 Pfizer Inc.; Exhibit 130: Pfizer Inc. - Overview; Exhibit 131: Pfizer Inc. - Product / Service; Exhibit 132: Pfizer Inc. - Key news; Exhibit 133: Pfizer Inc. - Key offerings; 12.14 Sanofi SA; Exhibit 134: Sanofi SA - Overview; Exhibit 135: Sanofi SA - Business segments; Exhibit 136: Sanofi SA - Key news; Exhibit 137: Sanofi SA - Key offerings; Exhibit 138: Sanofi SA - Segment focus; 12.15 Sun Pharmaceutical Industries Ltd.; Exhibit 139: Sun Pharmaceutical Industries Ltd. - Overview; Exhibit 140: Sun Pharmaceutical Industries Ltd. - Product / Service; Exhibit 141: Sun Pharmaceutical Industries Ltd. - Key news; Exhibit 142: Sun Pharmaceutical Industries Ltd. - Key offerings; 12.16 Teva Pharmaceutical Industries Ltd.; Exhibit 143: Teva Pharmaceutical Industries Ltd. - Overview; Exhibit 144: Teva Pharmaceutical Industries Ltd. - Business segments; Exhibit 145: Teva Pharmaceutical Industries Ltd. - Key news; Exhibit 146: Teva Pharmaceutical Industries Ltd. - Key offerings; Exhibit 147: Teva Pharmaceutical Industries Ltd. - Segment focus; 12.17 Viatris Inc.; Exhibit 148: Viatris Inc. - Overview; Exhibit 149: Viatris Inc. - Business segments; Exhibit 150: Viatris Inc. - Key news; Exhibit 151: Viatris Inc. - Key offerings; Exhibit 152: Viatris Inc. - Segment focus
13 Appendix: 13.1 Scope of the report; 13.2 Inclusions and exclusions checklist; Exhibit 153: Inclusions checklist; Exhibit 154: Exclusions checklist; 13.3 Currency conversion rates for US$; Exhibit 155: Currency conversion rates for US$; 13.4 Research methodology; Exhibit 156: Research methodology; Exhibit 157: Validation techniques employed for market sizing; Exhibit 158: Information sources; 13.5 List of abbreviations; Exhibit 159: List of abbreviations
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Country Market Characteristics; Exhibits4: Executive Summary - Chart on Market Segmentation by Type; Exhibits5: Executive Summary - Chart on Market Segmentation by Product; Exhibits6: Executive Summary - Chart on Market Segmentation by Application; Exhibits7: Executive Summary - Chart on Vendor Market Positioning; Exhibits8: Parent market; Exhibits9: Market Characteristics; Exhibits10: Offerings of vendors included in the market definition; Exhibits11: Market segments; Exhibits12: Chart on US - Market size and forecast 2023-2028 ($ billion); Exhibits13: Data Table on US - Market size and forecast 2023-2028 ($ billion); Exhibits14: Chart on US: Year-over-year growth 2023-2028 (%); Exhibits15: Data Table on US: Year-over-year growth 2023-2028 (%); Exhibits16: Historic Market Size - Data Table on active pharmaceutical ingredient (api) market in US 2018 - 2022 ($ billion); Exhibits17: Historic Market Size - Type Segment 2018 - 2022 ($ billion); Exhibits18: Historic Market Size - Product Segment 2018 - 2022 ($ billion); Exhibits19: Historic Market Size - Application Segment 2018 - 2022 ($ billion); Exhibits20: Five forces analysis - Comparison between 2023 and 2028; Exhibits21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; Exhibits22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; Exhibits23: Threat of new entrants - Impact of key factors in 2023 and 2028; Exhibits24: Threat of substitutes - Impact of key factors in 2023 and 2028; Exhibits25: Threat of rivalry - Impact of key factors in 2023 and 2028; Exhibits26: Chart on Market condition - Five forces 2023 and 2028; Exhibits27: Chart on Type - Market share 2023-2028 (%); Exhibits28: Data Table on Type - Market share 2023-2028 (%); Exhibits29: Chart on Comparison by Type; Exhibits30: Data Table on Comparison by Type; Exhibits31: Chart on Captive API - Market size and forecast 2023-2028 ($ billion); Exhibits32: Data Table on Captive API - Market size and forecast 2023-2028 ($ billion); Exhibits33: Chart on Captive API - Year-over-year growth 2023-2028 (%); Exhibits34: Data Table on Captive API - Year-over-year growth 2023-2028 (%); Exhibits35: Chart on Contract API - Market size and forecast 2023-2028 ($ billion); Exhibits36: Data Table on Contract API - Market size and forecast 2023-2028 ($ billion); Exhibits37: Chart on Contract API - Year-over-year growth 2023-2028 (%); Exhibits38: Data Table on Contract API - Year-over-year growth 2023-2028 (%); Exhibits39: Market opportunity by Type ($ billion); Exhibits40: Data Table on Market opportunity by Type ($ billion); Exhibits41: Chart on Product - Market share 2023-2028 (%); Exhibits42: Data Table on Product - Market share 2023-2028 (%); Exhibits43: Chart on Comparison by Product; Exhibits44: Data Table on Comparison by Product; Exhibits45: Chart on Generic - Market size and forecast 2023-2028 ($ billion); Exhibits46: Data Table on Generic - Market size and forecast 2023-2028 ($ billion); Exhibits47: Chart on Generic - Year-over-year growth 2023-2028 (%); Exhibits48: Data Table on Generic - Year-over-year growth 2023-2028 (%); Exhibits49: Chart on Innovative - Market size and forecast 2023-2028 ($ billion); Exhibits50: Data Table on Innovative - Market size and forecast 2023-2028 ($ billion); Exhibits51: Chart on Innovative - Year-over-year growth 2023-2028 (%); Exhibits52: Data Table on Innovative - Year-over-year growth 2023-2028 (%); Exhibits53: Market opportunity by Product ($ billion); Exhibits54: Data Table on Market opportunity by Product ($ billion); Exhibits55: Chart on Application - Market share 2023-2028 (%); Exhibits56: Data Table on Application - Market share 2023-2028 (%); Exhibits57: Chart on Comparison by Application; Exhibits58: Data Table on Comparison by Application; Exhibits59: Chart on Oncology - Market size and forecast 2023-2028 ($ billion); Exhibits60: Data Table on Oncology - Market size and forecast 2023-2028 ($ billion); Exhibits61: Chart on Oncology - Year-over-year growth 2023-2028 (%); Exhibits62: Data Table on Oncology - Year-over-year growth 2023-2028 (%); Exhibits63: Chart on Cardiovascular diseases - Market size and forecast 2023-2028 ($ billion); Exhibits64: Data Table on Cardiovascular diseases - Market size and forecast 2023-2028 ($ billion); Exhibits65: Chart on Cardiovascular diseases - Year-over-year growth 2023-2028 (%); Exhibits66: Data Table on Cardiovascular diseases - Year-over-year growth 2023-2028 (%); Exhibits67: Chart on Diabetes - Market size and forecast 2023-2028 ($ billion); Exhibits68: Data Table on Diabetes - Market size and forecast 2023-2028 ($ billion); Exhibits69: Chart on Diabetes - Year-over-year growth 2023-2028 (%); Exhibits70: Data Table on Diabetes - Year-over-year growth 2023-2028 (%); Exhibits71: Chart on Communicable diseases - Market size and forecast 2023-2028 ($ billion); Exhibits72: Data Table on Communicable diseases - Market size and forecast 2023-2028 ($ billion); Exhibits73: Chart on Communicable diseases - Year-over-year growth 2023-2028 (%); Exhibits74: Data Table on Communicable diseases - Year-over-year growth 2023-2028 (%); Exhibits75: Chart on Orthopedic and others - Market size and forecast 2023-2028 ($ billion); Exhibits76: Data Table on Orthopedic and others - Market size and forecast 2023-2028 ($ billion); Exhibits77: Chart on Orthopedic and others - Year-over-year growth 2023-2028 (%); Exhibits78: Data Table on Orthopedic and others - Year-over-year growth 2023-2028 (%); Exhibits79: Market opportunity by Application ($ billion); Exhibits80: Data Table on Market opportunity by Application ($ billion); Exhibits81: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits82: Impact of drivers and challenges in 2023 and 2028; Exhibits83: Overview on Criticality of inputs and Factors of differentiation; Exhibits84: Overview on factors of disruption; Exhibits85: Impact of key risks on business; Exhibits86: Vendors covered; Exhibits87: Matrix on vendor position and classification; Exhibits88: AbbVie Inc. - Overview; Exhibits89: AbbVie Inc. - Product / Service; Exhibits90: AbbVie Inc. - Key news; Exhibits91: AbbVie Inc. - Key offerings; Exhibits92: Amneal Pharmaceuticals Inc. - Overview; Exhibits93: Amneal Pharmaceuticals Inc. - Business segments; Exhibits94: Amneal Pharmaceuticals Inc. - Key news; Exhibits95: Amneal Pharmaceuticals Inc. - Key offerings; Exhibits96: Amneal Pharmaceuticals Inc. - Segment focus; Exhibits97: Aurobindo Pharma Ltd. - Overview; Exhibits98: Aurobindo Pharma Ltd. - Product / Service; Exhibits99: Aurobindo Pharma Ltd. - Key offerings; Exhibits100: Cadila Pharmaceuticals Ltd. - Overview; Exhibits101: Cadila Pharmaceuticals Ltd. - Product / Service; Exhibits102: Cadila Pharmaceuticals Ltd. - Key offerings; Exhibits103: Cipla Ltd. - Overview; Exhibits104: Cipla Ltd. - Business segments; Exhibits105: Cipla Ltd. - Key news; Exhibits106: Cipla Ltd. - Key offerings; Exhibits107: Cipla Ltd. - Segment focus; Exhibits108: Dr Reddys Laboratories Ltd. - Overview; Exhibits109: Dr Reddys Laboratories Ltd. - Business segments; Exhibits110: Dr Reddys Laboratories Ltd. - Key offerings; Exhibits111: Dr Reddys Laboratories Ltd. - Segment focus; Exhibits112: GlaxoSmithKline Plc - Overview; Exhibits113: GlaxoSmithKline Plc - Business segments; Exhibits114: GlaxoSmithKline Plc - Key news; Exhibits115: GlaxoSmithKline Plc - Key offerings; Exhibits116: GlaxoSmithKline Plc - Segment focus; Exhibits117: Koninklijke DSM NV - Overview; Exhibits118: Koninklijke DSM NV - Business segments; Exhibits119: Koninklijke DSM NV - Key news; Exhibits120: Koninklijke DSM NV - Key offerings; Exhibits121: Koninklijke DSM NV - Segment focus; Exhibits122: Lupin Ltd. - Overview; Exhibits123: Lupin Ltd. - Product / Service; Exhibits124: Lupin Ltd. - Key news; Exhibits125: Lupin Ltd. - Key offerings; Exhibits126: Novartis AG - Overview; Exhibits127: Novartis AG - Business segments; Exhibits128: Novartis AG - Key offerings; Exhibits129: Novartis AG - Segment focus; Exhibits130: Pfizer Inc. - Overview; Exhibits131: Pfizer Inc. - Product / Service; Exhibits132: Pfizer Inc. - Key news; Exhibits133: Pfizer Inc. - Key offerings; Exhibits134: Sanofi SA - Overview; Exhibits135: Sanofi SA - Business segments; Exhibits136: Sanofi SA - Key news; Exhibits137: Sanofi SA - Key offerings; Exhibits138: Sanofi SA - Segment focus; Exhibits139: Sun Pharmaceutical Industries Ltd. - Overview; Exhibits140: Sun Pharmaceutical Industries Ltd. - Product / Service; Exhibits141: Sun Pharmaceutical Industries Ltd. - Key news; Exhibits142: Sun Pharmaceutical Industries Ltd. - Key offerings; Exhibits143: Teva Pharmaceutical Industries Ltd. - Overview; Exhibits144: Teva Pharmaceutical Industries Ltd. - Business segments; Exhibits145: Teva Pharmaceutical Industries Ltd. - Key news; Exhibits146: Teva Pharmaceutical Industries Ltd. - Key offerings; Exhibits147: Teva Pharmaceutical Industries Ltd. - Segment focus; Exhibits148: Viatris Inc. - Overview; Exhibits149: Viatris Inc. - Business segments; Exhibits150: Viatris Inc. - Key news; Exhibits151: Viatris Inc. - Key offerings; Exhibits152: Viatris Inc. - Segment focus; Exhibits153: Inclusions checklist; Exhibits154: Exclusions checklist; Exhibits155: Currency conversion rates for US$; Exhibits156: Research methodology; Exhibits157: Validation techniques employed for market sizing; Exhibits158: Information sources; Exhibits159: List of abbreviations